Anavex Life Sciences Corp (AVXL)

[rx7171]

The recently approved monoclonal antibodies had CDR-SB as their primary end point.
CDR-SB measures both cognitive and functional improvement so that Blarcamsine did not reach statistical significance in ADL but did in CDR-SB 🤷‍♂️

Blarcasine’s CDR-SB data is much better so if it had been the sole primary end point the issue of the “missed” ADL data at 48 weeks would not be used by shorts to undermine its probability of approval.